Results of the LUX-Lung 7 trial met two of its co-primary endpoints, in progression-free survival and time to treatment failure, with EGFR-directed therapy Gilotrif (afatinib) compared to Iressa (gefitinib) in the first-line treatment of patients with advanced non-small cell lung cancer.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe